Ky\u014drin Pharmaceutical’s financial results for the fiscal year ending March 2026 show sales of 126.2 billion yen and net profit of 3.4 billion yen, a decline compared to the previous year. The forecast for 2027 suggests sales of 121.8 billion yen and net profit of 1.5 billion yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Ky\u014drin Pharmaceutical","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4569-20260512-02.pdf","jir_short_summary":"Ky\u014drin Pharmaceutical's financial results for the fiscal year ending March 2026 show sales of 126.2 billion yen and net profit of 3.4 billion yen, a decline compared to the previous year. The forecast for 2027 suggests sales of 121.8 billion yen and net profit of 1.5 billion yen.","jir_summary":"### Overview of Financial Performance\nKy\u014drin Pharmaceutical's consolidated results for the fiscal year ending March 2026 show sales of 126.2 billion yen, a decrease of 3.5% from the previous year, and operating income of 3.6 billion yen, a 43.9% decline. Net income attributable to owners of the parent was 3.4 billion yen, a significant decrease of 56.5%. While income from domestic new pharmaceuticals increased, gains were offset by declining revenues from overseas pharmaceuticals and one-time licensing income. The outlook for 2027 anticipates sales of 121.8 billion yen and net profit of 1.5 billion yen. Increased R&D and selling, general and administrative expenses have also contributed to profit pressure.\n\n### Future Outlook and Impact on Shareholders\nThe forecast for 2027 indicates a significant reduction in sales to 121.8 billion yen and net profit to 1.5 billion yen, raising concerns about decreasing profit margins. However, expansion of domestic new drugs and progress in pipeline development offer positive prospects. Cost management and new drug adoption may improve future performance, but short-term profitability is expected to remain under pressure. Attention should be paid to dividends and share price impacts for shareholders.","jir_financial_highlights":"Sales: 126.2 billion yen (YoY -3.5%)\nNet Income Attributable to Owners of Parent: 3.4 billion yen (YoY -56.5%)\nOperating Income: 3.6 billion yen (YoY -43.9%)","jir_category":"","jir_hashtags":"#Ky\u014drinPharmaceutical, #IRFinancialResults, #JapaneseStocks","jir_key_figures":"Sales: 126.2 billion yen (YoY -3.5%)\nNet income attributable to owners of the parent: 3.4 billion yen (YoY -56.5%)\nOperating income: 3.6 billion yen (YoY -43.9%)","jir_meta_title":"\u3010Ky\u014drin Pharmaceutical\u30112026 Financial Results | Sales of 126.2 billion yen, Net Profit of 3.4 billion yen","jir_meta_description":"Ky\u014drin Pharmaceutical's financial results for the fiscal year ending March 2026 show sales of 126.2 billion yen and net profit of 3.4 billion yen, a decrease compared to the previous year. The forecast for 2027 suggests sales of 121.8 billion yen and net profit of 1.5 billion yen.","jir_og_title":"\u3010Ky\u014drin Pharmaceutical\u30112026 Financial Results | Sales of 126.2 billion yen, Net Profit of 3.4 billion yen","jir_og_description":"Ky\u014drin Pharmaceutical's 2026 financial results show sales of 126.2 billion yen and net profit of 3.4 billion yen. The forecast for 2027 suggests sales of 121.8 billion yen and net profit of 1.5 billion yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48157","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n